

Asthma Indicators for LHIN 1: Erie St. Clair

Indicator	Asthma Indicators for LHIN 1: Erie St. Clair																						
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017*	2018*
1. PFT used for diagnosis (% of incident asthma) [†]	46.49	49.70	48.60	49.61	51.97	49.62	50.02	48.05	47.41	50.87	52.54	53.96	56.28	56.87	55.50	54.78	58.69	58.90	62.76	60.82	63.62	65.60	66.77
2. PFT used for monitoring (% of prevalent asthma) [†]	16.46	14.30	13.85	12.82	11.57	11.25	11.06	9.58	8.45	8.43	8.89	9.51	9.17	9.18	9.20	8.80	8.45	7.90	8.16	8.48	8.93	9.23	9.54
3. ≥1 ICS prescription (% of prevalent asthma) [‡]	54.50	52.31	51.65	50.70	50.87	49.19	48.66	46.30	45.40	45.31	45.45	45.15	45.41	45.59	46.28	47.45	47.76	48.38	47.60	47.62	47.33	44.31	41.65
4. ≥1 β2-agonist prescription (% of prevalent asthma) [‡]	60.71	58.98	58.01	56.49	56.17	53.25	51.23	47.48	45.58	44.72	43.68	41.78	40.42	39.95	39.34	39.06	39.41	38.77	35.83	25.12	25.03	24.29	23.72
5. ≥1 asthma ED visit (% of prevalent asthma)	6.24	4.71	3.49	3.24	2.91	2.55	2.55	2.17	2.37	2.03	1.88	1.79	1.56	1.45	1.29	1.20	1.11	1.06	0.91	1.00	0.92	0.81	0.75
6. ≥1 asthma physician office visit (% of prevalent asthma)	37.98	32.99	31.69	29.64	27.04	26.24	24.26	22.23	21.13	20.88	19.80	19.27	17.82	16.56	16.16	15.28	14.55	13.56	13.23	13.61	13.07	13.54	13.40
7. β2-agonist use (% of prevalent asthma) [‡]																							
0	39.29	41.02	41.99	43.51	43.83	46.75	48.77	52.52	54.42	55.28	56.32	58.22	59.58	60.05	60.66	60.94	60.59	61.23	64.17	74.88	74.97	75.71	76.28
1-2	19.38	19.83	19.82	19.60	20.19	19.22	18.72	17.57	17.47	18.14	17.60	17.67	17.95	18.24	17.85	17.36	18.12	17.79	16.38	11.81	11.74	11.27	11.24
≥3	41.32	39.15	38.19	36.89	35.98	34.02	32.51	29.91	28.10	26.59	26.07	24.10	22.48	21.71	21.48	21.70	21.30	20.98	19.45	13.31	13.29	13.03	12.48

*Reporting period is from April 1996 to March 2019. Data for 2017 and 2018 may be incomplete due to the 2-year algorithm to identify asthma, and numbers are subject to change.

PFT = pulmonary function test; ICS = inhaled corticosteroid; ED = emergency department; ODB = Ontario Drug Benefit; OHIP = Ontario Health Insurance Plan; LHIN = Local Health Integration Network; HSU = health services use

[†]PFT data refers to individuals aged 7-99 years in the asthma prevalent population.

[‡]Drug use data refers to individuals aged 66-99 years with complete year ODB coverage in the asthma prevalent population.

Technical notes:

^aOHIP data was up to December 2019 when the tables were created.

^bFor asthma incidence from July 2017 to March 2019, PFT data for 2.5-year post asthma incidence are not complete as latest data were available up to December 2019 when the tables were created.

^cIndividuals with missing LHIN, rurality, or without OHIP coverage were excluded.

^dAsthma incidence of the year were excluded from this table, except for indicator 1.

^eIndex date is defined as the first service date of asthma HSU, or any HSU if there was no asthma HSU, or April 1 if there was no HSU during the year.

Asthma indicators - detailed description:

1. Percent of asthma incidence aged 7 years and above with a PFT in one year prior to or 2.5 years after incidence date^{a-c}
2. Percent of asthma prevalence aged 7 years and above with a PFT in one year prior to the index date^{a,c-e}
3. Percent of asthma prevalence 66 years and above with at least one prescription of ICS in one year prior to the index date^{c-e}
4. Percent of asthma prevalence aged 66 years and above with at least one prescription of β2-agonist in one year prior to the index date^{c-e}
5. Percent of asthma prevalence with at least one ED visit in one year prior to the index date^{c-e}
6. Percent of asthma prevalence with at least one physician office visit in one year prior to the index date^{c-e}
7. Distribution of the three categories of β2-agonist use for asthma prevalence aged 66 years and above^{c,d}

Source: This table uses statistics reported by the Ontario Asthma Surveillance Information System (OASIS) and data provided by ICES, Ontario.